The Seed to Series A Funding Gap: How Australian Founders Bridge It Without Emergency Dilution

There's a period in every R&D company's life that nobody really names. Seed capital is deployed. Revenue isn't predictable enough for Series A metrics. The next raise is somewhere between six and twelve months away. Maybe longer. And the team is running out of time to get there.

Founders know this period intimately. They just don't have a clean word for it. The Seed to Series A gap is where good companies stall, where cap tables get permanently damaged, and where founders make the most expensive decisions of their company's life under the worst possible conditions.

What the Seed to Series A Gap Actually Is

The gap isn't a failure of planning. It's structural. Most Seed rounds are sized to get a company to a specific milestone: product launch, first customers, initial revenue. Series A investors expect to see a different set of metrics: predictable revenue, a working commercial model, and evidence that the business can scale.

The problem is that getting from one to the other takes longer than the Seed runway covers. Almost always. For R&D companies specifically, it takes even longer, because the milestones that matter to Series A investors: commercial traction, recurring revenue, a validated customer base. These are downstream of a long build cycle that the Seed round funded.

So the gap opens up. The Seed capital is spent. The product is built or nearly built. But the commercial metrics aren't there yet. And the runway is running out.

This is the moment most founders either handle well or don't.

Why It's Harder for R&D Companies

Any startup faces the Seed to Series A gap. R&D companies face a version of it with extra weight on each end.

On the left side of the gap, R&D companies spend longer in the build phase. A medtech company working through a clinical pathway, an agritech business running multi-year field trials, a deep tech company building hardware that works. These companies don't ship a product in six months and start collecting revenue. The build is the point. It's also expensive, ongoing, and doesn't generate cash.

On the right side, the Series A metrics that matter to institutional investors: monthly recurring revenue, net revenue retention, a clear unit economics story. These are harder to demonstrate when the commercial phase has barely started.

And underneath all of it, there's a timing mismatch that most guides don't mention. R&D companies accumulate a significant R&D Tax Incentive refund throughout the year, based on their eligible expenditure. That refund is real. It's committed capital the Australian Government will pay back. But it doesn't arrive until after the financial year ends, after the claim is lodged, after the ATO processes it. Typically October to December at the earliest.

So a company can be burning $150,000 a month, sitting on $400,000 in accruing R&D refund, and showing only eight weeks of runway on its bank statement. The capital exists. The timing gap means it can't be accessed when the pressure is highest.

That's the specific shape of the Seed to Series A gap for an R&D company. Capital spent, refund deferred, metrics not yet there, and a Series A still months away.

What Emergency Dilution Actually Costs

When founders run out of runway before the Series A is ready, the default move is to raise a bridge. A small extension round from existing investors, a new angel, or a strategic investor willing to come in at a lower entry point.

The problem isn't that bridge rounds are wrong. Sometimes they're the right call. The problem is what they cost when they happen under pressure.

Take a company that raised its Seed at a $6 million valuation. It's now 18 months later. The product is live, there are early customers, but the revenue is still too lumpy for a proper Series A. The founders have four months of runway. They need eight months to get to the metrics they want.

If they raise a bridge at this moment, they're raising from a position of obvious need. Investors know it. Terms reflect it. A $1 million bridge at a $5 million valuation, below the Seed price, creates a down round. It signals distress to future investors. It resets the cap table in ways that compound at every subsequent round.

The founders who do best in Series A negotiations are the ones who arrive with options. Not desperation.

The dilutive vs non-dilutive framework explains this in more depth, specifically how to identify whether what you're facing is a capital problem or a timing problem, because the answer determines which tool you should reach for.

The Four Bridge Options (And What They Actually Cost)

When runway is short and the Series A isn't ready, there are four things founders reach for. They're not equal.

Grants

Available, non-dilutive, and genuinely free when you get them. The problem is the timeline. Australian government grants: Entrepreneurs' Programme, CRC grants, export grants. These take months to assess and months more to disburse. If you have six weeks of runway, a grant application started today won't save you. Grants are a runway extension tool when used proactively, not reactively.

Revenue-based financing

Works when you have revenue to base it on. Most R&D companies at the Seed to Series A inflection point don't have predictable monthly revenue yet. Revenue-based financing providers require a track record, usually six to twelve months of consistent monthly receipts, before they'll advance against it. For pre-revenue or lumpy-revenue R&D companies, this option often doesn't exist.

Venture debt

Available, and faster than a grant. But venture debt typically comes with warrants, small equity stakes the lender receives as part of the deal, and covenants that restrict what you can do with the capital. It also requires revenue traction or strong investor backing to access. And the interest compounds. A $1 million venture debt facility at 12% over 18 months costs $180,000 in interest before accounting for the warrant dilution. That's real money for a company in the gap.

R&D financing

The least understood of the four options, and often the most relevant for eligible companies.

If your business has eligible R&D spend accruing this financial year, you're building toward an R&D Tax Incentive refund. That refund is a committed receivable. Not a projection, not a maybe. The Australian Government has structured a program to pay it back. R&D financing lets you access that anticipated refund before the ATO processes your claim.

No monthly interest payments against your cash position. No warrants. No equity. The facility is repaid when the ATO refund arrives. The cost is a financing fee, assessed against the size and timing of the anticipated refund.

For a company with $500,000 in eligible R&D spend accruing, the expected refund at 43.5% is approximately $217,500. Accessing 80% of that early gives you $174,000 of working capital. That's potentially two to four months of additional runway, depending on your burn rate.

Two to four months is the difference between a Series A from a position of strength and a bridge round from a position of need.

The Decision Framework: Which Option Is Right for You

Use the right tool for the actual problem. Before reaching for any of the options above, answer two questions.

Is this a capital problem or a timing problem?

A capital problem means you need money that doesn't exist yet. You're funding a new hire, a market entry, a product extension. The money you need hasn't been earned. In that case, equity or venture debt may be the right answer. They're bringing in new capital.

A timing problem means the capital exists but it's stuck in a future payment. An R&D refund, a signed contract awaiting invoice, a confirmed grant awaiting disbursement. In that case, giving up equity to solve a timing problem is expensive and permanent. The dilution stays after the timing problem resolves.

How long do you actually need?

Be precise. If you need three months to hit a specific revenue milestone that makes the Series A viable, a facility that covers three months is what you need. Don't raise six months of bridge if three months solves the problem. Every extra month of bridge capital you raise has a cost, whether it's interest, dilution, or both.

‍

Why R&D Financing Is Often the Cleanest Bridge for Eligible Companies

The framing matters here. R&D financing isn't a loan against your assets. It isn't equity. It's early access to capital you've already earned.

The distinction matters because it changes how it sits on your balance sheet, how it reads to future investors, and what it costs the company in the long run. A facility repaid from an ATO refund doesn't create permanent debt. It doesn't dilute the cap table. When the refund arrives and the facility is repaid, the balance sheet is clean.

That's the profile investors want to see when they're doing Series A due diligence. A company that managed its cashflow gap without emergency dilution and without taking on debt it couldn't service looks fundamentally different from a company that bridge-raised at a down-round valuation.

Understanding your real runway, including the R&D refund as a committed receivable in your calculation, is the starting point. A company that appears to have eight weeks of runway on its bank statement may have five months of real runway once the accruing refund is factored in. That calculation changes what decisions are available.